# Maravai LifeSciences Holdings, Inc. (MRVI) FY2026 YTD Q2 P&L / Income Statement

- Company: Maravai LifeSciences Holdings, Inc. (MRVI)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-07, accession number 0001823239-26-000059
- Page: https://plicit.ai/financials/mrvi/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/mrvi-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Business Segment by Geography

Income statement for 2026-01-01 through 2026-06-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 117,279,000 US dollars
- **Cost of revenue**: 62,928,000 US dollars
- **Gross profit**: 54,351,000 US dollars
- **Operating expenses (calculated)**: 71,598,000 US dollars
- **Loss from operations**: negative 17,247,000 US dollars
- **Other income (expense), net (calculated)**: negative 11,083,000 US dollars
- **Loss before income taxes**: negative 28,330,000 US dollars
- **Income tax benefit**: negative 322,000 US dollars
- **Net loss**: negative 28,008,000 US dollars
- **Cygnus - Latin and Central America**: 439,000 US dollars
- **Cygnus - Asia Pacific**: 11,581,000 US dollars
- **Cygnus - North America**: 14,374,000 US dollars
- **Cygnus - Europe, the Middle East and Africa**: 8,740,000 US dollars
- **TriLink - Latin and Central America**: 276,000 US dollars
- **TriLink - Asia Pacific**: 5,610,000 US dollars
- **TriLink - North America**: 52,599,000 US dollars
- **TriLink - Europe, the Middle East and Africa**: 23,660,000 US dollars
- **Selling, general and administrative**: 61,162,000 US dollars
- **Research and development**: 7,591,000 US dollars
- **Goodwill impairment**: 0 US dollars
- **Restructuring**: 2,845,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Maravai LifeSciences Holdings, Inc.: −$16.15 M; to noncontrolling interests: −$11.86 M.

## Chart details: Revenue by Business Segment

- Page: https://plicit.ai/financials/mrvi/fy2026-ytd-q2-income-statement/revenue-by-business-segment
- Chart image: https://plicit.ai/charts/mrvi-fy2026-ytd-q2-revenue-by-business-segment-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 117,279,000 US dollars
- **Cost of revenue**: 62,928,000 US dollars
- **Gross profit**: 54,351,000 US dollars
- **Operating expenses (calculated)**: 71,598,000 US dollars
- **Loss from operations**: negative 17,247,000 US dollars
- **Other income (expense), net (calculated)**: negative 11,083,000 US dollars
- **Loss before income taxes**: negative 28,330,000 US dollars
- **Income tax benefit**: negative 322,000 US dollars
- **Net loss**: negative 28,008,000 US dollars
- **TriLink**: 82,145,000 US dollars
- **Cygnus**: 35,134,000 US dollars
- **Selling, general and administrative**: 61,162,000 US dollars
- **Research and development**: 7,591,000 US dollars
- **Goodwill impairment**: 0 US dollars
- **Restructuring**: 2,845,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Maravai LifeSciences Holdings, Inc.: −$16.15 M; to noncontrolling interests: −$11.86 M.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/mrvi/fy2026-ytd-q2-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/mrvi-fy2026-ytd-q2-revenue-by-geography-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 117,279,000 US dollars
- **Cost of revenue**: 62,928,000 US dollars
- **Gross profit**: 54,351,000 US dollars
- **Operating expenses (calculated)**: 71,598,000 US dollars
- **Loss from operations**: negative 17,247,000 US dollars
- **Other income (expense), net (calculated)**: negative 11,083,000 US dollars
- **Loss before income taxes**: negative 28,330,000 US dollars
- **Income tax benefit**: negative 322,000 US dollars
- **Net loss**: negative 28,008,000 US dollars
- **North America**: 66,973,000 US dollars
- **Europe, the Middle East and Africa**: 32,400,000 US dollars
- **Asia Pacific**: 17,191,000 US dollars
- **Latin and Central America**: 715,000 US dollars
- **Selling, general and administrative**: 61,162,000 US dollars
- **Research and development**: 7,591,000 US dollars
- **Goodwill impairment**: 0 US dollars
- **Restructuring**: 2,845,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Maravai LifeSciences Holdings, Inc.: −$16.15 M; to noncontrolling interests: −$11.86 M.